Sara Carter, the former investigative journalist and Fox News contributor now serving as White House drug czar, has spent her early months emphasizing fentanyl, trafficking and addiction, not marijuana reform. Cannabis may still move through federal channels, but it is clearly not the part of drug policy this White House wants to lead with.
If you wanted a clearer read on where the Trump administration is putting its drug-policy energy, Sara Carter just gave it to you. The former investigative journalist and Fox News contributor, now serving as director of the Office of National Drug Control Policy, has used her early public rollout to emphasize fentanyl interdiction, addiction treatment, trafficking networks and synthetic drug threats, not marijuana reform. In her interview with Bloomberg Government, that priority order came through clearly, and it matches how the White House itself introduced her after her January confirmation.
That does not mean cannabis is gone from the federal conversation. It does mean cannabis is not what this administration wants to lead its drug-policy story with. In December, Trump signed an executive order aimed at increasing medical marijuana and cannabidiol research, and the White House said the administration wanted the attorney general to move expeditiously on the still-pending rescheduling process. Those were real signals, and they mattered. But they arrived alongside a much louder message coming from the administration’s drug-policy apparatus: fentanyl, overdose, trafficking and recovery come first.
That distinction is more important than a lot of people in cannabis want to admit. A policy can still move without being politically central. An open file is not the same thing as a flagship issue. Right now, the White House appears comfortable letting marijuana reform continue through administrative channels while spending its most visible time and capital on a harder-edged drug narrative, one built around enforcement, public safety and lives lost to illicit supply.
You can see that posture across Carter’s early activity. At the U.N. Commission on Narcotic Drugs in Vienna this month, she emphasized transnational criminal organizations, precursor chemicals and synthetic drug threats, framing the administration’s approach around combating criminal enterprises tied to the illicit drug trade. That is not a cannabis-first message. It is a clear statement of priority, and it helps explain why marijuana reform, even when it remains active on paper, does not look like the centerpiece of this White House’s drug-policy identity.
None of this means rescheduling cannot still happen. It means the industry should stop treating it like the White House’s main event. For months, parts of the cannabis industry and community have talked about reform as if the biggest question in Washington were when officials would finally decide to finish the job. Carter’s early rollout suggests something else: in this administration, the most urgent drug-policy conversation is about overdose, trafficking and addiction, not marijuana. Cannabis is still in play, but it is not where the administration seems most eager to plant its flag.
For operators, investors and advocates, that does not call for panic. It calls for perspective. Marijuana reform may still advance through memos, orders and agency process, but anyone expecting a full-throated White House push is probably reading more momentum into the moment than the public record supports. At least for now, this administration’s drug-policy identity is being built around fentanyl, addiction and enforcement. Cannabis may still move, but it is clearly not the part of drug policy this White House wants to lead with.
Photo: Shutterstock
